🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

38 results for “ophthalmic” Clear

  1. 0.05% Voclosporin Ophthalmic Solution (VOS)

    Aurinia Pharmaceuticals

    Dry Eye Syndrome

    phase 3 small molecule completed

    1 trial

  2. A matching sterile product (Placebo Ophthalmic Solution) will be provided using the same excipient formulation as the active K-321 product., Ripasudil

    The George Institute

    Fuchs Endothelial Corneal Dystrophy

    phase 3 small molecule active

    1 trial

  3. ADX-102 Ophthalmic Solution (0.5%)

    Aldeyra Therapeutics

    Non-infectious Anterior Uveitis

    phase 3 small molecule completed

    1 trial

  4. Aceclidine+Brimonidine combination ophthalmic solution

    LENZ Therapeutics

    Presbyopia

    phase 3 small molecule completed

    6 trials

  5. Ozempic 1 mg solution for injection in pre-filled pen, Semaglutide placebo, solution for injection in 1.5 mL pre-filled PDS290 pen injector

    NovoThirteen

    While it is well-established that long-term good glycaemic control will reduce the risk of diabetic retinopathy development and progression, intensification of glycaemic control has also been associated with an initial worsening of diabetic retinopathy. This phenomenon is known as “early worsening”. The rationale of this trial is to establish the long-term effects of semaglutide on diabetic retinopathy in subjects with type 2 diabetes (T2D) using validated and standardised ophthalmic assessments. This trial is a post-authorisation safety study (PASS) conducted as a commitment to the European Medicines Agency

    phase 3 small molecule active

    1 trial

  6. Pred Forte 10 mg/ml colirio en suspensión, Clobetasol propionate ophthalmic nanoemulsion, 0.05%

    Laboratorios Tillomed Spain S.L.U

    Inflammation and pain associated with ocular surgery

    phase 3 small molecule active

    1 trial

  7. Reproxalap Ophthalmic Solution (0.25%)

    Aldeyra Therapeutics

    Dry Eye Disease

    phase 3 small molecule completed

    4 trials

  8. Reproxalap Ophthalmic Solution (0.25%)

    Aldeyra Therapeutics

    Dry Eye

    phase 3 small molecule completed

    4 trials

  9. Reproxalap Ophthalmic Solution (0.25%)

    Aldeyra Therapeutics

    Allergic Conjunctivitis

    phase 3 small molecule completed

    4 trials

  10. Reproxalap Ophthalmic Solution (0.25%) QID

    Aldeyra Therapeutics

    Dry Eye

    phase 3 small molecule completed

    1 trial

  11. Test - Bimatoprost 0.01% Ophthalmic Solution

    Amneal Pharma Europe Ltd

    Glaucoma, Open-Angle

    phase 3 small molecule active

    1 trial

  12. bimatoprost ophthalmic solution formulation A

    Allergan Pharmaceuticals International Limited

    Glaucoma

    phase 3 small molecule terminated

    1 trial

  13. ADX-102 Ophthalmic Drops (0.5%)

    Aldeyra Therapeutics

    Conjunctivitis, Allergic

    phase 2 small molecule completed

    1 trial

  14. ADX-102 Ophthalmic Solution (0.5%)

    Aldeyra Therapeutics

    Dry Eye Syndromes

    phase 2 small molecule completed

    1 trial

  15. FST-100 Ophthalmic Suspension

    Takeda

    Acute Adenoviral Conjunctivitis

    phase 2 small molecule terminated

    1 trial

  16. Gatifloxacin 0.3% ophthalmic solution

    Allergan Pharmaceuticals International Limited

    Acute Bacterial Corneal Ulcers

    phase 2 small molecule completed

    1 trial

  17. NS2 Ophthalmic Drops (0.5%)

    Aldeyra Therapeutics

    Allergic Conjunctivitis

    phase 2 small molecule completed

    1 trial

  18. Nebivolol Ophthalmic Suspension 1 Percent

    Summit Therapeutics

    Open-Angle Glaucoma

    phase 2 small molecule completed

    1 trial

  19. Preservative-free, ophthalmic solution

    Laboratoire HRA Pharma

    Paediatric myopia

    phase 2 small molecule active

    1 trial

  20. R348 Ophthalmic Solution, 0.2%

    RIGEL PHARMACEUTICALS INC

    Keratoconjunctivitis Sicca

    phase 2 small molecule completed

    2 trials

  21. R348 Ophthalmic Solution, 0.2%

    RIGEL PHARMACEUTICALS INC

    Chronic Graft-versus-host Disease

    phase 2 small molecule completed

    1 trial

  22. Reproxalap Ophthalmic Solution (0.25% Novel Formulation) QID to BID

    Aldeyra Therapeutics

    Dry Eye

    phase 2 small molecule completed

    1 trial

  23. Reproxalap Ophthalmic Solution (0.25%)

    Aldeyra Therapeutics

    Dry Eye Syndromes

    phase 2 small molecule completed

    1 trial

  24. Reproxalap Ophthalmic Solution (0.25%)

    Aldeyra Therapeutics

    Dry Eye Syndrome

    phase 2 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources